ImageneBio, Inc. (NASDAQ:IMA) Receives Consensus Rating of “Hold” from Brokerages

ImageneBio, Inc. (NASDAQ:IMA) has been assigned a consensus recommendation of “Hold” from the five research firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $30.00.

A number of equities analysts have recently commented on IMA shares. HC Wainwright assumed coverage on shares of ImageneBio in a report on Friday. They issued a “buy” rating on the stock. Wall Street Zen cut ImageneBio from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 17th. Wedbush reaffirmed an “underperform” rating on shares of ImageneBio in a research note on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of ImageneBio in a report on Monday, June 29th.

ImageneBio Stock Down 1.4%

Shares of NASDAQ IMA opened at $5.61 on Friday. The stock’s 50-day simple moving average is $5.79 and its two-hundred day simple moving average is $5.87. ImageneBio has a twelve month low of $3.94 and a twelve month high of $14.34. The firm has a market capitalization of $63.67 million, a P/E ratio of -1.22 and a beta of 0.76.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.27. As a group, research analysts anticipate that ImageneBio will post -3.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Stonepine Capital Management LLC bought a new stake in shares of ImageneBio in the 2nd quarter worth approximately $539,044,000. Trails Edge Capital Partners LP bought a new stake in ImageneBio in the second quarter worth $1,663,824,000. Hsbc Holdings PLC purchased a new stake in ImageneBio during the second quarter valued at about $208,000. Cable Car Capital LP bought a new position in shares of ImageneBio during the second quarter valued at about $4,611,000. Finally, Blue Owl Capital Holdings LP purchased a new position in shares of ImageneBio in the second quarter worth about $5,414,000. 75.00% of the stock is owned by hedge funds and other institutional investors.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.